Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charlotte Borocco has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Galeotti

    Paediatric Rheumatology, Bicêtre Hospital, APHP , Le Kremlin-Bicêtre, France

    2 shared publications
  • Isabelle Koné-Paut

    Pediatric Rheumatology, centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, Assistance Publique-Hôpitaux de Paris, Université Paris-Sud, Bicêtre Hospital, 78 rue du General Leclerc, 94275 Le Kremlin-Bicêtre cedex, France

    2 shared publications
  • Isabelle Koné-Paut

    Department of Pediatric Rheumatology, National Reference Centre for Auto-Inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris Saclay Le Kremlin Bicêtre, Paris, France

    2 shared publications
  • Adam Reinhardt

    A. Reinhardt, MD, Department of Pediatrics, Boys Town National Research Hospital, Omaha, Nebraska, USA

    1 shared publication
  • Adrien Schvartz

    Paediatric Rheumatology, Bicêtre Hospital, APHP , Le Kremlin-Bicêtre, France

    1 shared publication
  • Alexandre Belot

    Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    Contribution of Ultrasound in Current Practice for Managing Juvenile Idiopathic Arthritis

    by Charlotte Borocco, Federica Anselmi, Linda Rossi-Semerano

    The interest and application of musculoskeletal ultrasound (MSUS) in juvenile idiopathic arthritis (JIA) are increasing. Numerous studies have shown that MSUS is more sensitive than clinical examination for detecting subclinical synovitis. MSUS is a well-accepted tool, easily accessible and non-irradiating. Therefore, it is a useful technique throughout JIA management. In the diagnostic work-up, MSUS allows for better characterizing the inflammatory involvement. It helps to define the disease extension, improving the classification of patients into JIA subtypes. Moreover, it is an essential tool for guiding intra-articular and peritendinous procedures. Finally, during the follow-up, in detecting subclinical disease activity, MSUS can be helpful in therapeutic decision-making. Because of several peculiarities related to the growing skeleton, the MSUS standards defined for adults do not apply to children. During the last decade, many teams have made large efforts to define normal and pathological US features in children in different age groups, which should be considered during the US examination. This review describes the specificities of MSUS in children, its applications in clinical practice, and its integration into the new JIA treat-to-target therapeutic approach.


  • Atypical polyarticular juvenile idiopathic arthritis revealing multicentric reticulohistiocytosis with pulmonary involvement

    by Anna Gaussem, Perrine Dusser, Van Huynh, Caroline Galeotti, Adrien Schvartz, Léa Jaume, Linda Rossi-Semerano, Isabelle Koné-Paut, Charlotte Borocco

    Dear Editor, Multicentric reticulohistiocytosis (MRH) is a rare systemic disease affecting mainly adults and most frequently associating joint and skin involvement. Other rare organ involvement should be investigated. Here, we report the first case of MRH in an adolescent with a pulmonary involvement. A 13-year-old boy was admitted with wrist and metacarpophalangeal arthritis associated with Achilles tendon enthesitis. The first diagnosis was enthesitis-related JIA in the absence of psoriasis. He had no family history of rheumatological or digestive conditions. Initial blood tests did not show any abnormal acute phase reactant levels, blood cell counts were normal, ANA titres were positive at 1/160, and HLA-B27 and rheumatoid factor findings were negative. From disease onset, he had multiple non-itchy nodules over the extension face of the elbows ( Fig. 1A). He started a first treatment with non-steroidal anti-inflammatory drugs and MTX with initial efficacy on joints. After 9 months of treatment, he had a relapse, with polyarthritis affecting the small joints of the hands but without enthesitis. New lab tests revealed positivity for rheumatoid factor at 477 UI/ml and eosinophilia count up to 1.5 G/l. A new diagnosis was polyarticular JIA. He started treatment with adalimumab associated with MTX, which led to an amelioration of the arthritis. After 10 months of this treatment, the boy had a relapse again, which led to a further change in therapy to etanercept and MTX. Etanercept was quickly stopped because of an allergic reaction in the form of a painful skin rash and was replaced with intravenous tocilizumab. Unfortunately, this treatment was insufficient and led to further arthritis, joint deformities ( Fig. 1B), fatigue and weight loss. The boy then received intravenous abatacept. With these different biotherapies, many infections appeared, such as septic arthritis, appendicitis and herpes zoster. The work-up including complete blood count, immunoglobulin levels, vaccine titres and immunophenotyping remained normal. We finally performed a biopsy of the persistent skin nodules, which revealed dermal histiocytic proliferation positive for CD68 and CD163 and negative for CD1a and PS100 on immunohistochemical staining associated with multinucleated giant cells. These histological features then allowed for the diagnosis of MRH. A new extensive work-up showed a mild biological inflammation (erythrocyte sedimentation rate 54 mm/h and CRP level 15 mg/l). Chest CT revealed non-specific interstitial lung disease with a cluster of subpleural honeycomb cysts, diffuse ill-defined centrilobular micronodules, ground-glass opacities and reticulation ( Fig. 1C–E). Respiratory function tests showed a moderate restrictive syndrome. Cardiac ultrasonography gave normal results, as did fluorodeoxyglucose-PET/CT. Repeated ophthalmological examinations from the beginning of the disease were all normal. We concluded a diagnosis of MRH with skin, joint and lung involvement. The boy started treatment with infliximab associated with MTX, corticosteroids and bisphosphonates (zoledronate). After 6 months’ follow-up, he was in complete joint remission, and corticosteroids were gradually reduced to a dose of 0.1 mg/kg/day. Chest CT showed a disappearance of the micronodules. Skin lesions decreased in size, with healing of excoriated nodules.


  • SARS-CoV-2-associated Henoch–Schönlein purpura in a 13-year-old girl

    by Charlotte Borocco, Céline Lafay, Inès Plantard, Jeremy Gottlieb, Isabelle Koné-Paut, Caroline Galeotti


  • Open Access

    Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis

    by Justine Maller, Emily Fox, K.T. Park, Sarah Sertial Paul, Kevin Baszis, Charlotte Borocco, Sampath Prahalad, Pierre Quartier, Adam Reinhardt, Dieneke Schonenberg-Meinema, et al.

    Objective: The incidence of inflammatory bowel disease (IBD) in juvenile idiopathic arthritis (JIA) is higher than in the general pediatric population. However, reports of IBD in the systemic JIA (sJIA) subtype are limited. We sought to characterize sJIA patients diagnosed with IBD and to identify potential contributing risk factors.Methods: Using an internationally distributed survey, we identified 16 patients with sJIA who were subsequently diagnosed with IBD (sJIA-IBD cohort). Five hundred twenty-two sJIA patients without IBD were identified from the CARRA Legacy Registry and served as the sJIA-only cohort for comparison. Differences in demographic, clinical characteristics, and therapy were assessed using chi-square test, Fisher exact test,t-test, and univariate and multivariate logistic regression, as appropriate.Results: Of the patients with sJIA-IBD, 75% had a persistent sJIA course and 25% had a history of macrophage activation syndrome. sJIA-IBD subjects were older at sJIA diagnosis, more often non-White, had a higher rate of IBD family history, and were more frequently treated with etanercept or canakinumab compared to sJIA-only subjects. Sixty-nine percent of sJIA-IBD patients successfully discontinued sJIA medications following IBD diagnosis, and sJIA symptoms resolved in 9 of 12 patients treated with tumor necrosis factor-α (TNF-α) inhibitors.Conclusion: IBD in the setting of sJIA is a rare occurrence. The favorable response of sJIA symptoms to therapeutic TNF-α inhibition suggests that the sJIA-IBD cohort may represent a mechanistically distinct sJIA subgroup. Our study highlights the importance of maintaining a high level of suspicion for IBD when gastrointestinal involvement occurs in patients with sJIA and the likely broad benefit of TNF-α inhibition in those cases.


  • Open Access

    The French paediatric cohort of Castleman disease: a retrospective report of 23 patients

    by Charlotte Borocco, Claire Ballot-Schmit, Oanez Ackermann, Nathalie Aladjidi, Jeremie Delaleu, Vannina Giacobbi-Milet, Sarah Jannier, Eric Jeziorski, François Maurier, Yves Perel, et al.

    Background: Castleman disease (CD) is a rare non-malignant lymphoproliferation of undetermined origin. Two major disease phenotypes can be distinguished: unicentric CD (UCD) and multicentric CD (MCD). Diagnosis confirmation is based on histopathological findings in a lymph node. We attempted to survey all cases of paediatric CD identified to date in France to set up a national registry aiming to improve CD early recognition, treatment and follow-up, within the context of a new national reference center (http://www.castleman.fr). Methods: In 2016, we e-mailed a questionnaire to members of the French paediatric immunohaematology society, the paediatric rheumatology society and the Reference Centre for Castleman Disease to retrospectively collect cases of paediatric CD (first symptoms before age 18 years). Anatomopathological confirmation was mandatory. Results: We identified 23 patients (12 girls) with a diagnosis of UCD (n = 17) and MCD (n = 6) between 1994 and 2018. The mean age at first symptoms was 11.47 ± 4.23 years for UCD and 8.3 ± 3.4 years for MCD. The mean diagnosis delay was 8.16 ± 10.32 months for UCD and 5.16 ± 5.81 years for MCD. In UCD, the initial symptoms were isolated lymph nodes (n = 10) or lymph node associated with other symptoms (n = 7); fever was present in 3 patients. Five patients with MCD presented fever. No patients had HIV or human herpesvirus 8 infection. Autoinflammatory gene mutations were investigated in five patients. One patient with MCD carried a K695R heterozygous mutation in MEFV, another patient with MCD and Duchenne myopathy carried two variants in TNFRSF1A and one patient with UCD and fever episodes carried two heterozygous mutations, in IL10RA and IL36RN, respectively. Treatment of UCD was mainly surgical resection, steroids, and radiotherapy. Treatment of MCD included tocilizumab, rituximab, anakinra, steroids, chemotherapy, and splenectomy. Overall survival after a mean of 6.1 ± 6.4 years of follow-up, was 100% for both forms. Conclusion: Paediatric CD still seems underdiagnosed, with a significant diagnosis delay, especially for MCD, but new international criteria will help in the future. Unlike adult CD, which is strongly associated with HIV and human herpesvirus 8 infection, paediatric CD could be favored by primary activation of innate immunity and may affect life expectancy less.


  • Néphropathies non amyloïdes dans les maladies auto-inflammatoires : à propos de 20 cas français

    by C. Borocco, I. Kone-Paut, G. Grateau, T. Ulinski, A. Belot, M. Desjonquères, C. Miceli, A. Karras, B. Moulin, J.J. Boffa, et al.